Navigation Links
Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd
Date:2/28/2011

VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- Allon Therapeutics Inc. (TSX: NPC), today announced that Gordon C. McCauley, President and CEO, will present at RetailInvestorConferences.com.DATE:

March 3rd, 2011TIME:

3:00 PM ESTLINK:

www.retailinvestorconferences.comThis will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Allon Therapeutics Inc.:Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA. This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" and based in Vancouver.

For additional information please visit the company's website: www.allontherapeutics.com

About RetailInvestorConferences.com:RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Forward-Looking Statements:Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.


'/>"/>

SOURCE Allon Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
2. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
3. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
4. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
5. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
6. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
7. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
10. Echo Therapeutics Announces Appointments to Board of Directors
11. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Fresh Wave® ... Liquid eco-friendly odor-control solution for colleges and universities at the APPA 2017 ... effectively eliminate severe cannabis and tobacco smoke odors without the use of harsh chemicals, ...
(Date:7/21/2017)... ... 2017 , ... Hospital M&A activity slowed in the second quarter of 2017, ... rose to 23 in the second quarter, up 15% from the 20 publicly announced ... deals in the year-ago second quarter. Only four of the transactions disclosed a purchase ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
Breaking Medicine News(10 mins):